Jim Banting is the Assistant Vice-Principal (Partnerships and Innovation) at Queen’s University. His career began as a co-founder of the Queen’s spin-off company named Vaxis Therapeutics. Vaxis was venture capital-funded, grown, and sold to a U.S. specialty pharmaceutical company. A large portion of Jim’s career has entailed a focus on partnerships, licensing, and M & A, in the biotech sector in the United States. He returned to Canada in 2014 to serve as President & CEO of PARTEQ Innovations, the commercialization unit for Queen’s, which has since been incorporated into Queen’s University Partnerships and Innovation unit, established in 2017, within the office of the VP Research. He holds Ph.D. and B.Sc.H. degrees from Queen’s University.